Aladul, MI, Fitzpatrick, RW and Chapman, SR ORCID: https://orcid.org/0000-0002-0326-7742 (2017) Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK. BioDrugs, 31 (6). 533 - 544.

[img] Text
Biosimilars and biological DMARDS clean version.docx - Accepted Version

Download (87kB)

Abstract

OBJECTIVE: Biological disease-modifying antirheumatic drugs (bDMARDs) are effective but expensive options for treating rheumatoid arthritis. The introduction of infliximab and etanercept biosimilars presents a significant potential cost saving in a financially constrained health system such as the National Health Service (NHS) in the UK. This study examines the impact of the introduction of infliximab and etanercept biosimilars on the utilisation of bDMARDs and subsequent budget impact. METHODS: We conducted an interrupted time series analysis of secondary care utilisation data in rheumatology specialities from the DEFINE database, between March 2014 and February 2017. RESULTS: The cumulative cost savings from the introduction of infliximab and etanercept biosimilars was £38.8 million over 2 years. There was a statistically significant increase in average monthly utilisation of bDMARDs for adalimumab (0.48%), certolizumab pegol (1.90%), golimumab (3.06%), abatacept (2.97%) and tocilizumab (2.24%), but not for etanercept. In contrast, the overall utilisation of infliximab decreased slightly by an average of 0.03% per month. The introduction of infliximab biosimilars negatively affected the monthly utilisation of branded infliximab significantly. Similarly, the introduction of an etanercept biosimilar negatively affected the monthly utilisation of branded etanercept significantly. CONCLUSIONS: The introduction of bDMARDs biosimilars has resulted in considerable cost savings to the NHS, with the branded products reducing their prices in response to the availability of less expensive biosimilars and competition between the biosimilars themselves. Our results also suggest that when a biosimilar is available for a directly comparable branded molecule, price is the key influencing factor in the prescribing of a specific product.

Item Type: Article
Additional Information: This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Adis International Ltd. at http://doi.org/10.1007/s40259-017-0252-3 - please refer to any applicable terms of use of the publisher.
Uncontrolled Keywords: Antirheumatic Agents, Arthritis, Rheumatoid, Biosimilar Pharmaceuticals, Budgets, Costs and Cost Analysis, Etanercept, Humans, Infliximab, Interrupted Time Series Analysis, State Medicine, United Kingdom
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Medicine and Health Sciences > School of Pharmacy
Related URLs:
Depositing User: Symplectic
Date Deposited: 12 Mar 2021 15:14
Last Modified: 12 Mar 2021 15:18
URI: https://eprints.keele.ac.uk/id/eprint/9244

Actions (login required)

View Item View Item